Hepatitis A Vaccines Market Size, Share & Industry Analysis, By Type (Inactivated, Live Attenuated, and Others), By Age Group (Pediatric and Adults), By Form (Solution and Lyophilized Powder), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast, 2025-2032

The global hepatitis A vaccines market size was valued at USD 1.24 billion in 2024. The market is projected to grow from USD 1.26 billion in 2025 to USD 2.57 billion in 2032 at a CAGR of 10.7% during the forecast period. North America dominated the hepatitis A vaccines market with a market share of 50% in 2024.

Hepatitis A is a liver disease caused by hepatitis A virus (HAV) infection. The HAV is transmitted by ingesting contaminated food and water or by close physical contact with an infected person. A person with hepatitis A infection is in an asymptomatic state or may develop symptoms such as fever, nausea or vomiting, abdominal discomfort, jaundice, and acute liver failure. The vaccination for hepatitis A is considered an effective and safe method to prevent hepatitis A infection. Furthermore, the rising prevalence of hepatitis A and increasing government initiatives to raise immunization coverage are propelling the demand and adoption of the hepatitis A vaccines.

• For instance, in February 2024, per the data published by the European Centre for Disease Prevention and Control (ECDC), 2022, 30 EU/EEA countries reported 4,548 cases of hepatitis A, with one case rate per 100,000 populations. The increasing number of cases associated with the diseases is expected to increase demand for preventive measures to decrease the overall healthcare expenditure due to disease progression.

Moreover, the presence of key players such as GSK plc, Sanofi, and Merck & Co. Inc., with regulatory-approved products for hepatitis A vaccines, boosts the market's growth.

MARKET DYNAMICS

MARKET DRIVERS

Rising Prevalence of Hepatitis A Boosts Market Growth

The increasing prevalence of hepatitis A globally is one of the major factors driving market growth. Hepatitis A is an inflammation of the liver, which can lead to mild to severe illness. The disease is spread due to ingestion of contaminated food and water, inadequate sanitation, poor personal hygiene, and oral-anal sex. Additionally, this infection is very common in low- and middle-income countries with poor sanitary conditions and hygienic practices.

• For example, in February 2024, the Committee on Sanitary-Epidemiological Welfare and Public Health, Maftuna Saidova, Uzbekistan, reported that around 9,507 children were infected with hepatitis A in the first two months of 2024. Such a high number of cases in two months increases the need for active vaccination in these countries.

MARKET RESTRAINTS

High Cost and Limited Access in Low-Income Regions Restrict Market Growth

Vaccine production involves costly clinical trials, regulatory compliance, and cold-chain manufacturing, leading to increased overall costs of development and final product. Furthermore, high costs limit the product’s access in lower-income regions, which acts as major restraints for the hepatitis A vaccine market growth.

Inadequate healthcare infrastructure and limited public awareness in low-income regions hinder vaccine delivery and uptake. Due to its high cost, the per-dose price of hepatitis A vaccines remain unaffordable for many public health systems in developing nations.

• For instance, as per the American British Cowdray Medical Center, the cost per dose of the hepatitis A vaccine in Mexico is USD 935.7, and a minimum of 2 doses are required for complete immunization. Also, the cost of vaccination for Hepatitis A/B is USD 1,016.8. Such higher costs associated with vaccines may hamper their adoption in the lower-income population.

As a result, hepatitis A outbreaks continue in underserved regions, highlighting gaps in prevention efforts. The disparity in vaccine availability challenges global eradication goals.

MARKET OPPORTUNITIES

Emerging Market and Indigenous Vaccine Development to Offer Lucrative Growth Opportunity

Emerging markets, particularly in Asia, Latin America, and Africa, offer market expansion opportunities. These regions have high disease burden due to poor sanitation, limited access to clean water, and overcrowded living conditions, making them priority areas for vaccination.

However, the high cost of imported vaccines makes it more difficult for these countries to meet local demand. Thus, India and China have shifted their focus to developing indigenous vaccines, which improve accessibility and reduce healthcare costs, to fulfill the unmet needs of the growing population.

• For instance, in January 2024, Indian Immunologicals Ltd (IIL) launched Havisure. It is India’s first indigenously developed hepatitis A vaccine. This vaccine development offers a significant step toward India's fight against hepatitis A and substantially contributes to public health.

Such advancements and product launches by the regional companies reduce the reliance on the global supply chain and boost the market growth during the forecast period.

MARKET CHALLENGES

Inefficient Cold-Chain Logistics to Challenge Hepatitis A Vaccines Market Growth

Logistics support is a critical factor for ensuring effective immunization services. To ensure the potency of the vaccines, it must be stored at temperatures between 2 and 8°C. Deviations from this temperature range can result in reduced effectiveness or even complete loss of efficacy. Thus, maintaining the cold chain during storage and transportation is crucial to prevent temperature excursions that could compromise the quality of vaccines.

Moreover, the inefficiency of the authorities in the lower income countries to maintain proper storage conditions leads to the wastage of vaccines and inefficient vaccination coverage. Such factors affect the immunization rate and thus challenge the hepatitis A vaccines market growth.

Hepatitis A Vaccines Market Trends

Rising Demand for Travelers’ Immunization to Demonstrate Future Growth

The rising global travel has increased the demand for traveler immunization, a key trend driving the hepatitis A vaccine market. Travel clinics and pharmacies are witnessing increased uptake of hepatitis A vaccines, especially among tourists, business travelers, and military personnel. This has expanded the market in high-income countries where travel-related vaccination is recommended.

• For instance, in August 2019, the South Korean community recommended two doses of hepatitis A vaccine for infection prevention, and at least one dose is strongly recommended before travel to countries where hepatitis A poses a risk.

Such activities signal a shift toward adopting vaccination and global hepatitis B therapeutic market growth.

Download Free sample to learn more about this report.

SEGMENTATION ANALYSIS

By Type

Rising Approval for Inactivated Vaccines Boost Segment's Growth

Based on type, the global market is segmented into inactivated, live attenuated, and others.

The inactivated segment had the highest global hepatitis A vaccines market share in 2024. The inactivated hepatitis A vaccine contains the hepatitis A antigen virus in inactivated form. Once administered, it aids in developing immunity by producing antibodies against it. Key market products augment the segment's growth in an inactivate form, which is available internationally.

Additionally, rising approval for inactivated vaccines across the globe is expected to boost the segment’s growth in the market.

• For instance, in February 2023, SINOVAC, China, announced that the Ministry of Health of the Kyrgyz Republic had approved its inactivated hepatitis A vaccine, Healive.

The live attenuated segment held a significant portion of the market and is expected to grow at a slower pace during the forecast period. The live attenuated vaccine is created by reducing the virulence of a pathogen, but still keeping it viable. The slower growth of the segment is due to its availability in India and China and is part of their national immunization program.

• According to the data published by the World Health Organization, more than 10 million doses of H2 and L-A-1 vaccines are used annually in China.

By Age Group

Pediatrics is Set Lead Due to its Effective Vaccination Protocols

Based on age group, the segment is bifurcated into pediatric and adults.

The pediatric segment is expected to lead the global market and grow with a significant CAGR during the forecast period. The presence of effective vaccination protocols for pediatrics across the globe drives the segment's higher share.

• For instance, in January 2025, as per the data published by the U.S. Center for Disease Control and Prevention, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination for children of ages 12–23 months and catch-up vaccination for children aged 2–18 years who have not previously received hepatitis A vaccine. Such recommendations increase the vaccination number for pediatrics and are expected to increase product adoption.

The adult segment held a considerable share of the market. In adults, the vaccination is indicated for any person who is not fully vaccinated and requests vaccination during travel, if exposed to the hepatitis A virus during work, or having an HIV infection. Additionally, the rising incidence of hepatitis A among adults and symptomatic illness due to HAV increases the demand for hepatitis A vaccinations among adults.

By Form

Presence of Key Products in Solution Form to Boost the Segment’s Growth

Based on form, the market is classified into lyophilized powder and solution.

The solution dosage form holds a leading position in the market. The precise delivery and controlled dosage of solution form enhances the clinical utility. Also, most of the key vaccines available for hepatitis A are in solution form, thus expected to hold a dominant share of the market.

• For example, Vaqta by Merck & Co., Inc. and HAVRIX by GSK plc are in solution form.

On the other hand, the lyophilized powder form segment held a considerable market share in 2024. The benefits associated with the lyophilized powder are its longer shelf life, ease of storage, and convenience for administration. It is mostly preferred for its stability and quick reconstitution during procedures.

By Distribution Channel

Government Suppliers Segment to Exhibit High Growth in the Near Future

Based on distribution channel, the market is segmented into hospital & retail pharmacies, government suppliers, and others.

In terms of distribution channels, the government suppliers held the largest share of the market. This is primarily due to procuring vaccine doses in large volumes from the manufacturers in millions, and mainly focusing on supplying to countries with limited reach.

Moreover, rising funding activities by government suppliers to offer immunization to the lower economic countries boosts the growth of the segment.

• For instance, in May 2025, the Global Alliance for Vaccines and Immunization (GAVI) contributed more than USD 250.0 million to lower-income countries to support immunization programs, intending to protect the world against the threat of infectious diseases.

On the other hand, the hospital & retail pharmacies segment is projected to witness substantial growth during the forecast period, driven by the easy availability of vaccination and scheduled dosage for pediatrics in these settings, increasing the distribution of these vaccines via hospital & retail pharmacies.

Hepatitis A Vaccines Market Regional Outlook

By region, the global market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America’s market size stood at USD 0.62 billion in 2024 and is expected to dominate the global market during the forecast period. The presence of advanced healthcare facilities with effective immunization programs for early immunization and the presence of key players with robust products for hepatitis A immunization are boosting the region’s growth.

U.S.

The U.S. dominated the North American region, owing to the rising incidence of diseases among high risk populations and availability of vaccines at an affordable price at clinics and pharmacies propel the market’s growth in the U.S.

• For instance, in October 2022, as per data presented by the CDC's Division of Viral Hepatitis (DVH), reported a swift rise in several cases in 37 U.S. states from August 2016 to October 2020. The division reported hepatitis A outbreaks involving approximately 44,660 cases in the period. Such a rising number of cases associated with viral hepatitis increased the adoption of preventive care and thus resulted in boosting the market growth.

Asia Pacific

The Asia Pacific market held the second-largest share and is estimated to grow at the highest CAGR in the forecast period. The rising number of cases and presence of key players with indigenous vaccine development strategies, increase the product adoption.

• For instance, in July 2024, as per the data reported by GAVI, the number of hepatitis A cases in Kerala, India, were more than 6,000 in the first half of 2024, more than the total cases in 2023, which were 1,073.

Europe

Europe held the third-largest share of the market owing to the presence of advanced healthcare facilities with adequate vaccination programs.

• For instance, in May 2025, NHS initiated the world-first vaccine program to prevent gonorrhea. As per the program, the government aims to offer vaccines for mpox, hepatitis A and B, and human papillomavirus (HPV) vaccination to people with an appointment for the gonorrhea vaccine. Such programs boost the adoption of the products and market for hepatitis A vaccines.

Latin America and the Middle East & Africa

Latin America and the Middle East & Africa held comparatively lower shares but are expected to grow during the forecast period. The growth of the Hepatitis A regional market is augmented by the increasing prevalence of hepatitis A in this region due to poor sanitary conditions and hygienic practices. However, rising initiatives to eliminate viral hepatitis propel the market’s growth in the region.

• For instance, in July 2024, RAK Hospital hosted a health talk on Hepatitis A and B. The discussion covered topics such as prevention, symptoms, and treatment of these diseases. The event aimed to raise awareness and encourage healthier lifestyles among attendees.

COMPETITIVE LANDSCAPE

KEY INDUSTRY PLAYERS

GSK plc and Sanofi Company Are Key Players Owing to Their Robust Product Portfolio

This market holds a consolidated competitive structure with players such as GSK plc, Sanofi, Merck & Co., Inc., who accounted for a substantial share in 2024. The top market players hold their position due to robust product offerings and consistent sales of key products in several regions.

Other key players with an important presence in the global and regional market include Indian Immunologicals Ltd (IIL), SINOVAC, Vaxines Trading, Inc., and Boryung Biopharma Co., with new product launches and initiatives for expanding globally. Such activities are expected to maintain their position in the market.

LIST OF KEY HEPATITIS A VACCINES COMPANIES PROFILED

• GSK plc (U.K.)
• Sanofi (France)
• Merck & Co., Inc. (U.S.)
• Wockhardt (India)
• Indian Immunologicals Ltd (IIL) (India)
• SINOVAC (China)
• Vaxines Trading, Inc. (Philippines)
• Boryung Biopharma Co. (South Korea)

KEY INDUSTRY DEVELOPMENTS

• May 2025 - Sanofi collaborated with Vietnam Vaccine Company (VNVC) to build a new plant for vaccine production in Vietnam.
• July 2024 - SINOVAC collaborated with the China Foundation for Hepatitis Prevention and Control to hold a conference on "Hepatitis A Prevention and Control Technology and Vaccination” in Beijing.
• April 2023 - Sanofi launched AVAXIM Junior in the U.K. It is an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years, as a preventive measure from hepatitis A virus.
• March 2021 - Boryung Biopharma Co. announced that the Hepatitis A vaccine developed by using the cell culture method was proven effective on Korean subjects.
• June 2019 - Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted for incorporating VAQTA (Hepatitis A Vaccine, Inactivated) under routine vaccination of children.

REPORT COVERAGE

The global hepatitis A vaccines market analysis focuses on key aspects, such as the epidemiology of hepatitis A, in key countries and regions. Additionally, the market report includes pipeline analysis, vaccination coverage by key countries, and an overview of reimbursement scenarios by different countries. Furthermore, insights on key industry developments such as mergers, partnerships, and acquisitions, and new product launches are mentioned in the report. Besides these, it offers insights into regional analysis, and the market trends in hepatitis A vaccine development.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation